Tuesday, November 17, 2015

News: Economic Analysis Demonstrates Substantial Spine Surgery Cost Savings with TranS1 AxiaLIF

DENVER--()--The AxiaLIF procedure from TranS1®, a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine, provides an estimated savings of $3,500 when compared to the Transformational Lumbar Interbody Fusion (TLIF) surgery option according to a recent study. Axial Lumbar Interbody Fusion (AxiaLIF) is designed to create a reproducible anterior retroperitoneal pre-sacral access route to the L5-S1 vertebral bodies.

Scott Parker, MD, director of the Spinal Column Surgical Quality and Outcomes Research Laboratory at Vanderbilt University, and Matt McGirt, MD, of Carolina Neurosurgery and Spine Associates, jointly authored the economic analysis1 in 2014. The key takeaways show that AxiaLIF patients have:
  • An average cost savings per procedure of $3,500
  • Shortened hospital stays
  • Lower rates of hospital readmission, a key metric hospitals work to avoid
  • Faster return to work
“We want patients to recognize AxiaLIF as a minimally invasive, safe, effective and affordable surgery. The pre-sacral approach allows many patients to leave the hospital within hours of surgery,” said Jeffrey Schell, CEO of TranS1.
AxiaLIF was acquired by Quandary Medical in 2014 and is approved by Medicare (CPT code 22586), making the procedure available to millions of Americans. With more than 14,000 surgeries performed in the United States, AxiaLIF can be a viable option for patients requiring interspinal fusion of the L5-S1 vertebrae.
Headquartered in Denver, TranS1 was restructured under new ownership in 2015 and features a product line that provides a foundation for living well driven by surgeon innovation. The restructured TranS1 team includes experienced research and development, sales and professional education professionals who are focused on resilient and continuous training of its sales force and physician customers, employing best in class training methods that ultimately benefit patients. TranS1’s primary product, AxiaLIF, provides a strong foundation upon a healthy L5-S1 joint to enable patients to live well. For more information, please visit www.TranS1.com.


For TranS1
Melissa Christensen, 720-833-5918

Published at BusinessWire

No comments:

Post a Comment